drugset / Trial / NCT01491594

Eltrombopag for the Prevention of Chemotherapy Induced Thrombocytopenia

NCT01491594

Phase 1 Terminated 1 enrolled Duke University GlaxoSmithKline · collab
NaSingle-groupOpen-labelPrevention

Summary

The purpose of this study is to study the effect of eltrombopag on chemotherapy induced thrombocytopenia. Thrombocytopenia is when there is a low number of platelets in the blood. Sometimes, thrombocytopenia occurs as a side effect of chemotherapy treatments.

Timeline

Start
2012-04
Primary completion
2013-03
Completion
2013-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Eltrombopag Small molecule 100 mg Oral
Subject Eltrombopag Small molecule 150 mg Oral
Subject Eltrombopag Small molecule 225 mg Oral
Subject Eltrombopag Small molecule 300 mg Oral